biostudies-literatureKang YMYin Shu-Tien Foundation Taipei Veterans General Hospital-National Yang-Ming University Excellent Physician Scientists CultivationMinistry of Education, Culture, Sports, Science and Technology of Japan1540-1551https://www.ebi.ac.uk/biostudies/studies/S-EPMC9883571biostudies-literatureUnknown12(2)<h4>Background</h4>To evaluate the clinical relative biological effectiveness (RBE) of carbon-ion radiotherapy (C-ion RT) for prostate cancer.<h4>Methods</h4>The records of 262 patients with low-risk prostate cancer (median age, 65 [47-80] years) treated with C-ion RT at QST Hospital, National Institutes for Quantum Science and Technology in Japan during 2000-2018 were reviewed retrospectively. Four different protocol outcomes and prostate-specific antigen (PSA) responses were evaluated. The median follow-up was 8.4 years. The Kaplan-Meier method was used to estimate the biochemical or clinical failure-free rate (BCFFR). Clinical RBE was calculated using the tumor control probability model.<h4>Results</h4>The 5-, 7-, and 10-year BCFFRs were 91.7%, 83.8%, and 73.2%, respectively. The 10-yeaCancer medicineThe clinical relative biological effectiveness and prostate-specific antigen kinetics of carbon-ion radiotherapy in low-risk prostate cancer.PMC988357121K0771109-V-A-008Inaniwa TLiu YMTsujii HKang YMIwai YOkonogi NTsuji HChao YKasuya GWakatsuki MMatsufuji NIshikawa HfalseThe clinical relative biological effectiveness and prostate-specific antigen kinetics of carbon-ion radiotherapy in low-risk prostate cancer.<h4>Background</h4>To evaluate the clinical relative biological effectiveness (RBE) of carbon-ion radiotherapy (C-ion RT) for prostate cancer.<h4>Methods</h4>The records of 262 patients with low-risk prostate cancer (median age, 65 [47-80] years) treated with C-ion RT at QST Hospital, National Institutes for Quantum Science and Technology in Japan during 2000-2018 were reviewed retrospectively. Four different protocol outcomes and prostate-specific antigen (PSA) responses were evaluated. The median follow-up was 8.4 years. The Kaplan-Meier method was used to estimate the biochemical or clinical failure-free rate (BCFFR). Clinical RBE was calculated using the tumor control probability model.<h4>Results</h4>The 5-, 7-, and 10-year BCFFRs were 91.7%, 83.8%, and 73.2%, respectively. The 10-yea2023-01-01T00:00:00Z2023 Jan2025-04-05T09:03:13.78Z2025-04-05T09:03:13.78ZS-EPMC98835713585214210.1002/cam4.5045